A Randomized, Double-Blind, Placebo-Controlled Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia

Completed
Phase of Trial: Phase II/III

Latest Information Update: 08 Jun 2017

At a glance

  • Drugs Deutetrabenazine (Primary)
  • Indications Drug-induced dyskinesia
  • Focus Registrational; Therapeutic Use
  • Acronyms ARM-TD
  • Sponsors Auspex Pharmaceuticals
  • Most Recent Events

    • 08 Jun 2017 Results (n=259) of pooled analysis of ARM-TD and AIM-TD studies assessing efficacy and safety of deutetrabenazine in reducing the severity of abnormal involuntary movements presented at the 21st International Congress of Parkinson's Disease and Movement Disorders.
    • 08 Jun 2017 Results (n=161) of pooled data from ARM-TD and AIM-TD studies presented at the 21st International Congress of Parkinson's Disease and Movement Disorders.
    • 08 Jun 2017 Results (n=259) assessing efficacy of deutetrabenazine from the pooled ARM-TD and AIM-TD data sets as compared with pooled placebo cohort, presented at the 21st International Congress of Parkinson's Disease and Movement Disorders
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top